Slide 1: Pfizer Pflash: A Spotlight on Clostridioides difficile (C. diff) Vaccine Development
Pfizer Pflash: A Spotlight on Clostridioides difficile (C. diff) Vaccine Development Classified – Confidential Presentation intended 1 for the investment community
Slide 2: Forward-Looking Statements and Other Notices
Our discussions during this presentation will include forward-looking recommendations; uncertainties regarding the impact of COVID-19 on statements that are subject to substantial risks and uncertainties that Pfizer’s business, operations and financial results; and competitive Forward-Looking could
Slide 3: Today's Speakers
Today’s Speakers Hosted by Francesca Annaliesa Alejandra Julie DeMartino Anderson Gurtman Skinner Chief Investor Head, Vaccine Research Senior Vice President, Vice President, Bacterial Relations Officer and Development Vaccine Clinical Research Vaccines and Technology and Development 3
Slide 4: Executing on Three Key Pillars in Vaccine Research & Development
Executing on Three Key Pillars in Vaccine Research & Development Targeting emerging health threats to drive potential long-term growth in viral and bacterial indications ENHANCE and Augment EXECUTE on Mid/Late- GROW Our Pipeline Core Franchises Stage Pipeline Portfolio C. difficile Lyme Disease Phas
Slide 5: C. difficile: Common & Potentially Fatal Healthcare Associated Infection
C. difficile: Common & Potentially Fatal Healthcare Associated Infection Individuals are 7-10 times more likely to contract C. difficile while on antibiotics or during following month1 Overview of C. difficile Infection (CDI) Cascade Disruption of C. difficile Toxins A and B released normal microbio
Slide 6: C. difficile Infection (CDI) is a Pressing Public Health Threat
C. difficile Infection (CDI) is a Pressing Public Health Threat Estimated to cause nearly One in eleven 500K annual infections people over 65 diagnosed with healthcare associated C. diff in the U.S.1 infection die within one month1 ~$5-6B No Vaccine currently available to prevent Estimated annual U.
Slide 7: First-Generation C. difficile Vaccine Candidate Phase 3 Study
First-Generation C. difficile Vaccine Candidate Phase 3 Study Phase 3 CLOVER study had potential to establish regulatory precedent │ Began 1Q’17 with data announced in 1Q’22 N = 17,535 Study Population C. diff Vaccine Candidate Primary Endpoints Adults ≥50 years old at increased R First CDI episode
Slide 8: Vaccination Reduced Symptom Duration & Medically Attended C. diff
Vaccination Reduced Symptom Duration & Medically Attended C. diff First-generation Phase 3 data demonstrated potential of vaccine candidate to reduce C. diff associated healthcare burden 100% Vaccine Efficacy Against Medically Attended C. diff 75% Reduction in Median C. diff Infection and C. diff In
Slide 9: Updated Formulation C. diff Vaccine Candidate in Phase 2
Updated Formulation C. diff Vaccine Candidate in Phase 2 Advanced to Phase 2 earlier this year based on encouraging safety and immunogenicity in Phase 1 First-Generation C. difficile Vaccine Candidate Antigen Antigen Dosing Regimen Modified C. diff Toxin A Modified C. diff Toxin B 3 Doses Over 6 Mon
Slide 10: Summary: C. difficile Vaccine Program
Summary: C. difficile Vaccine Program C. diff is a Pressing Public Health Threat with No First-Generation Candidate Approved Vaccine Demonstrated Potential to One in 11 people over age 65 Reduce C. diff Associated diagnosed with a healthcare Healthcare Burden in Phase 3 associated CDI die within one
Slide 11: Q&A Session
Q&A Session Moderated by Francesca Annaliesa Alejandra Julie DeMartino Anderson Gurtman Skinner Chief Investor Head, Vaccine Research Senior Vice President, Vice President, Bacterial Relations Officer and Development Vaccine Clinical Research Vaccines and Technology and Development 11